EQL PHARMA AB (7JK) — Cash Flow Reinvestment Rate
EQL PHARMA AB (7JK) has a Cash Flow Reinvestment Rate of 0.88x as of December 2025, reinvesting €11.87 Million (capex €11.87 Million ) from operating cash flow of €13.44 Million. Check EQL PHARMA AB cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
EQL PHARMA AB Cash Flow Reinvestment Rate (2022–2023)
Historical reinvestment intensity for EQL PHARMA AB across 2 annual periods. Explore cash flow to debt ratio of EQL PHARMA AB to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for EQL PHARMA AB (2022–2023)
Year-by-year capital reinvestment analysis for EQL PHARMA AB. For live market cap and broader valuation context, see 7JK market cap overview.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.74x | €20.51 Million | €27.62 Million | €20.51 Million | ▲ +40.6% |
| 2022 | 0.53x | €22.09 Million | €41.83 Million | €22.09 Million | — |